Page last updated: 2024-11-12
dibudipine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dibudipine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 10252115 |
CHEMBL ID | 1099187 |
MeSH ID | M0287177 |
Synonyms (3)
Synonym |
---|
ditert-butyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
CHEMBL1099187 |
dibudipine |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" Pharmacokinetic study: plasma samples were collected periodically after intravenous (0." | ( Application of a new high performance liquid chromatography method to the pharmacokinetics of dibudipine in rats. Bohlooli, S; Ghiaee, S; Keyhanfar, F; Mahmoudian, M, ) | 0.35 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" Also, it appeared that mebudipine had a slower rate of absorption compared with nifedipine (the time to reach peak hypotensive action at 2, 4 and 8 mg kg(-1) orally administered doses were, respectively, 24." | ( Effects of mebudipine and dibudipine, two new calcium-channel blockers, on rat left atrium, rat blood pressure and human internal mammary artery. Ghiaee, S; Mahmoudian, M; Mirkhani, H; Omrani, GR, 1999) | 0.6 |
" Oral bioavailability was low." | ( Application of a new high performance liquid chromatography method to the pharmacokinetics of dibudipine in rats. Bohlooli, S; Ghiaee, S; Keyhanfar, F; Mahmoudian, M, ) | 0.35 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (3)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID478856 | Selectivity ratio of antagonist activity at rat Cav1.3 to antagonist activity at rabbit Cav1.2 at 100 nM | 2010 | Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9 | Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. |
AID478851 | Antagonist activity at rabbit Cav1.2 expressed in HEK293 cells assessed as inhibition of voltage pulse-induced calcium current at 100 nM by FLIPR calcium 4 assay | 2010 | Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9 | Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. |
AID478846 | Antagonist activity at rat Cav1.3 expressed in HEK293 cells assessed as inhibition of voltage pulse-induced calcium current at 100 nM by FLIPR calcium 4 assay | 2010 | Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9 | Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (22.22) | 18.2507 |
2000's | 5 (55.56) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.36
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |